In Aripo and South Korea
Suven Life Sciences has received grant of one (1) product patent from Aripo (AP4415) and one (1) product patent from South Korea (10-18087922) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2033 and 2034 respectively.The granted claims of the patents include the class of selective 5-HT4 and 5-HT6 compounds respectively and are being developed as therapeutic agents for major depressive disorders and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Narcolepsy, Parkinson and Schizophrenia respectively.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
